Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2011 | Original Article

In vivo imaging of astrocytosis in Alzheimer’s disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study

Authors: Alexander Frizell Santillo, Juan Pablo Gambini, Lars Lannfelt, Bengt Långström, Luohija Ulla-Marja, Lena Kilander, Henry Engler

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2011

Abstract

Purpose

Astrocytosis is an important feature of the neuropathology of Alzheimer’s disease (AD), yet there is currently no way of detecting this phenomenon in vivo.

Methods

In this study we examine the retention of the positron emission tomography (PET) tracer ¹¹C-L-deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, ¹¹C-labelled Pittsburgh Compound B (PIB) retention was determined.

Results

Results show a significantly higher ¹¹C-L-DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values.

Conclusion

Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy.

Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 2009;16(3):378–85.PubMed

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009;66(1):60–7.PubMed

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358(9280):461–7.PubMed

Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 1990;80:419–25.PubMed

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994;62:15–30.PubMed

Wisniewski HM, Wegiel J. Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging 1991;12:593–600.PubMed

Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004;25:663–74.PubMed

Ekblom J, Jossan SS, Bergström M, Oreland L, Walum E, Aquilonius SM. Monoamine oxidase-B in astrocytes. Glia 1993;8(2):122–32.PubMed

Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A 1982;79(20):6385–9.PubMed

10.

Jossan SS, d’Argy R, Gillberg PG, Aquilonius SM, Långström B, Halldin C, et al. Localization of monoamine oxidase B in human brain by autoradiographical use of 11C-labelled L-deprenyl. J Neural Transm 1989;77:55–64.PubMed

11.

Jossan SS, Gillberg PG, Giotfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience 1991;45(1):1–12.PubMed

12.

Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980;49:1–20.PubMed

13.

Freedman NM, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med 2005;46(10):1618–24.PubMed

14.

Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 2009;85(5):506–12. Epub 2009 Jan 7.PubMed

15.

Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235(4787):481–5.PubMed

16.

Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995;36(7):1255–62.PubMed

17.

Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci 2007;255(1–2):17–22. Epub 2007 Mar 7.PubMed

18.

Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003;30(1):85–95.PubMed

19.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306–19.PubMed

20.

Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease. Brain 2011;134:301–17.PubMed

21.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129(Pt 11):2856–66. Epub 2006 Jul 19.PubMed

22.

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(10):1456–65. Epub 2007 May 11.PubMed

23.

Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250–60.PubMed

24.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMed

25.

McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 Suppl):417–23.PubMed

26.

Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–54.PubMed

27.

Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, et al. Mechanistic positron emission tomography studies: demonstration of deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain. J Neurochem 1988;51:1524–34.PubMed

28.

MacGregor RR, Fowler JS, Wolf AP, Halldin C, Langström B. Synthesis of suicide inhibitors of monoamine oxidase: carbon-11 labeled clorgyline, L-deprenyl and D-deprenyl. J Labelled Comp Radiopharm 1988;25:1–9.

29.

Bergström M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Långström B. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl—analysis of kinetic data. Acta Neurol Scand 1998;98:224–31.PubMed

30.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–72.PubMed

31.

Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimag J 2008;2:114–25.PubMed

32.

Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med 2011;52(2):173–9. Epub 2011 Jan 13.PubMed

33.

Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increase in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997;18(4):431–5.PubMed

34.

Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Prog Brain Res 1998;117:267–85.PubMed

35.

Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 1998;54:97–106.PubMed

36.

Nelson P, Jicha G, Schmitt F, Liu H, Davis D, Mendiondo M, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol 2007;66:1136–46.PubMed

Title: In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study
Authors: Alexander Frizell Santillo
Juan Pablo Gambini
Lars Lannfelt
Bengt Långström
Luohija Ulla-Marja
Lena Kilander
Henry Engler
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1895-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In vivo imaging of astrocytosis in Alzheimer’s disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2011

Reduction of artefacts caused by hip implants in CT-based attenuation-corrected PET images using 2-D interpolation of a virtual sinogram on an irregular grid

Nuclear medicine, scientific publishing and the era of cost containment

Radioembolisation of hepatocellular carcinoma patients using 90Y-labelled microspheres: towards a diffusion of the technique?

Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy

Functional implications of hippocampal degeneration in early Alzheimer’s disease: a combined DTI and PET study

Tony Theobald (ed): Sampson’s textbook of radiopharmacy (4th edition)